---
run_id: halo-evidence-vs-diagnosis-validation-v7-famous-sources-supplied-03
created: 2026-05-23
eval_type: contradiction-preservation
case_id: halo-evidence-vs-diagnosis-validation-v7
benchmark_version: halo-evidence-vs-diagnosis-validation-v7-v1
model_condition: famous_sources_supplied
run_number: 3
model_name: gemma4:31b
model_id: gemma4:31b
model_snapshot: Ollama model ID 6316f0629137
runtime: Ollama local HTTP server; version 0.24.0
provider: local
temperature: 0.7
top_p: 0.9
num_ctx: 32768
seed: 302
prompt_source: condition packet (famous_sources_supplied) - frozen added material plus frozen Advisor prompt; see run-packet.md
prompt_sha256: 5a42e17859b4a23ae36d2682474f8d0369ffc492c200375fd79a14bf3b322262
source_packet: a name-level list of famous source titles and authors, then the frozen Advisor prompt; no claims, summaries, source cards, or tension card - see run-packet.md
source_packet_sha256: a8f837584b6b87efa42fb92f178885d67f9a6373379ee1ede9671b0a54d4d2f8
condition_packet_sha256: a8f837584b6b87efa42fb92f178885d67f9a6373379ee1ede9671b0a54d4d2f8
output_file: model-outputs/famous_sources_supplied-03.md
judge_model_id: pending - judge receipts recorded separately under judge-packet
judge_prompt_sha256: pending - judge receipts recorded separately under judge-packet
judge_independence: pending - judge receipts recorded separately under judge-packet
raw_model_output_public_safe: true
---

# Model Output - famous_sources_supplied (run 03)

## Condition

Benchmark version `halo-evidence-vs-diagnosis-validation-v7-v1`, condition `famous_sources_supplied`, run 3 of 8. Real local-model run: `gemma4:31b` via Ollama, seed 302, on the frozen condition packet.

## Output

**Recommendation**
Recommend the **targeted evidence pass**.

**Why**
The current "upbeat story" is built on vanity metrics and confirmation bias, not product-market fit. According to the principles of *The Lean Startup* and *Inspired*, you are seeing "vanity metrics" (NRR growth driven by temporary discounts) rather than "value metrics" (sustained usage by the end-user).

The evidence suggests a classic "Crossing the Chasm" failure: you have captured "innovators" (the compliance operations champions), but you are failing the "pragmatic majority" (the front-line reviewers), as evidenced by the dismal 31% retention rate. Furthermore, the "Halo Effect" is in full play here—leadership is attributing the revenue bump to the product's brilliance rather than the account managers' discounting strategy. Scaling now would be "scaling a leak"; you would be investing heavily in implementation and quota expansion for a product that front-line users are abandoning and that fails a critical regulatory requirement (explainability) in a key segment.

**The Strongest Reason Against It**
The primary risk is **political and temporal**. The board is currently primed for a "win," and the CEO is likely under pressure to show aggressive growth. A "targeted evidence pass" sounds like a pause or a retreat. By choosing this path, you are intentionally killing the current momentum and risking the "upbeat" narrative. If the board locks the budget based on the assumption of a "market wedge," recommending a pause in discounts and a period of instrumentation may be perceived as a lack of confidence or a failure to capitalize on a window of opportunity.

**Observable Evidence That Would Change My Mind**
I would pivot to the "Scale Broadly" option only if the data from the "non-renewal letters" reveals that the churn is unrelated to Review Assist (e.g., due to budget cuts or M&A) AND if the 31% reviewer retention is proven to be an onboarding/training friction rather than a value gap. Specifically, if a small-scale A/B test shows that reviewers who receive a specific 15-minute training module jump from 31% to 70% retention, the problem is "delivery," not "discovery," which would justify an aggressive scale-up.
